Tikacad 90 Tablet
Marketer
Cadila Pharmaceuticals Ltd
Salt Composition
Ticagrelor (90mg)
Overview Tikacad 90 Tablet
CardioGuard 90mg tablets are antiplatelet agents, also known as blood thinners. They inhibit the formation of dangerous blood clots within blood vessels, thus lowering the risk of heart attack or stroke in patients with cardiac conditions. CardioGuard 90mg is also indicated for those who have recently experienced a heart attack, severe angina, or undergone cardiac stenting. Its use helps prevent future cardiac events, including recurrent heart attacks, stroke, and stent thrombosis. Concurrent use with aspirin, another antiplatelet drug, will likely be prescribed by your physician. CardioGuard 90mg can be ingested with or without food, consistently at the same time daily. Continued use is crucial, even during symptom-free periods, as discontinuation increases the risk of recurrent cardiac events. The most frequent adverse effect is bleeding; minor wounds may bleed longer than normal. This is typically mild and self-limiting. Some patients experience mild shortness of breath, which usually subsides with ongoing treatment. Report persistent bleeding or worsening/unresolved dyspnea to your doctor. CardioGuard 90mg is contraindicated in patients with active internal bleeding (e.g., stomach ulcers, intracranial hemorrhage) and those with liver disease. Disclose any such conditions to your physician prior to commencing treatment.
Primary Ingredients of Tikacad 90 Tablet
No text was provided to rewrite.
Uses of Tikacad 90 Tablet
Cardiovascular event prophylaxis
Major Benefits of Tikacad 90 Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Tikacad 90 Tablet whole; avoid chewing, crushing, or breaking it. Consumption with or without food is acceptable, but consistent timing is recommended.
Common Side effects of Tikacad 90 Tablet:
- Bleeding
- Breathlessness
How to use Tikacad 90 Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Tikacad 90 Tablet whole; avoid chewing, crushing, or breaking it. Consumption with or without food is acceptable, however, consistent timing is recommended.
How Tikacad 90 Tablet works:
Ticagrelor 90 mg tablets are a drug that inhibits platelet aggregation. Their mechanism of action involves blocking platelet adhesion, reducing the risk of dangerous thrombus development. Consequently, the likelihood of myocardial infarction or cerebrovascular accident is diminished.
SAFETY ADVICE
AlcoholCAUTION
Use of Tikacad 90 Tablet with alcohol requires careful consideration. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
The use of Tikacad 90 Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Patient consultation with their doctor is advised.
Breast feedingCONSULT YOUR DOCTOR
Data on Tikacad 90 Tablet use while breastfeeding is lacking. Seek medical advice from your physician.
DrivingSAFE
Driving ability is typically unaffected by Tikacad 90 Tablet.
KidneySAFE IF PRESCRIBED
Tikacad 90 tablets are considered safe for use in individuals with kidney impairment; no dosage modification is advised. Data regarding Tikacad 90 tablet use in patients undergoing renal dialysis is currently scarce.
LiverCAUTION
Patients with liver impairment should use Tikacad 90 Tablet cautiously, potentially requiring dose modification. Severe hepatic disease contraindicates the use of Tikacad 90 Tablet; physician consultation is advised.
What if you forget to take Tikacad 90 Tablet :
Should you forget a Tikacad 90 Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual regimen. Avoid taking a double dose.
Facts to Know About Tikacad 90 Tablet
| Label | Value |
|---|---|
| Chemical Type | Triazolo[1,5-a]pyrimidines |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
| Actions | ADP receptor antagonists (P2Y12 inhibitors) |




